Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.

Kimura T, Nakamura K, Miyoshi T, Yoshida M, Akazawa K, Saito Y, Akagi S, Ohno Y, Kondo M, Miura D, Wada J, Ito H.

Int Heart J. 2019 May 30;60(3):728-735. doi: 10.1536/ihj.18-392. Epub 2019 May 17.

2.

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.

Miyoshi T, Nakamura K, Miura D, Yoshida M, Saito Y, Akagi S, Ohno Y, Kondo M, Ito H.

Cardiol J. 2019;26(5):575-583. doi: 10.5603/CJ.a2018.0048. Epub 2018 May 2.

PMID:
29718530
3.

Suppression of Wnt Signaling and Osteogenic Changes in Vascular Smooth Muscle Cells by Eicosapentaenoic Acid.

Saito Y, Nakamura K, Miura D, Yunoki K, Miyoshi T, Yoshida M, Kawakita N, Kimura T, Kondo M, Sarashina T, Akagi S, Watanabe A, Nishii N, Morita H, Ito H.

Nutrients. 2017 Aug 10;9(8). pii: E858. doi: 10.3390/nu9080858.

4.

Eicosapentaenoic acid prevents arterial calcification in klotho mutant mice.

Nakamura K, Miura D, Saito Y, Yunoki K, Koyama Y, Satoh M, Kondo M, Osawa K, Hatipoglu OF, Miyoshi T, Yoshida M, Morita H, Ito H.

PLoS One. 2017 Aug 3;12(8):e0181009. doi: 10.1371/journal.pone.0181009. eCollection 2017.

5.

Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.

Akagi S, Nakamura K, Matsubara H, Kondo M, Miura D, Matoba T, Egashira K, Ito H.

J Cardiovasc Pharmacol. 2016 Apr;67(4):290-8. doi: 10.1097/FJC.0000000000000352.

6.

Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension.

Akagi S, Nakamura K, Miura D, Saito Y, Matsubara H, Ogawa A, Matoba T, Egashira K, Ito H.

Int Heart J. 2015 May 13;56(3):354-9. doi: 10.1536/ihj.14-338. Epub 2015 Apr 23.

7.

Electrocardiographic parameters and fatal arrhythmic events in patients with Brugada syndrome: combination of depolarization and repolarization abnormalities.

Tokioka K, Kusano KF, Morita H, Miura D, Nishii N, Nagase S, Nakamura K, Kohno K, Ito H, Ohe T.

J Am Coll Cardiol. 2014 May 27;63(20):2131-2138. doi: 10.1016/j.jacc.2014.01.072. Epub 2014 Apr 2.

8.

Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats.

Miyoshi T, Nakamura K, Yoshida M, Miura D, Oe H, Akagi S, Sugiyama H, Akazawa K, Yonezawa T, Wada J, Ito H.

Cardiovasc Diabetol. 2014 Feb 13;13:43. doi: 10.1186/1475-2840-13-43.

9.

[Oxidative stress and calcium overload in heart failure].

Nakamura K, Miura D, Matsubara H, Ito H.

Nihon Yakurigaku Zasshi. 2012 Dec;140(6):265-9. Japanese. No abstract available.

PMID:
23229632
10.

Increased passive stiffness of cardiomyocytes in the transverse direction and residual actin and myosin cross-bridge formation in hypertrophied rat hearts induced by chronic β-adrenergic stimulation.

Sumita Yoshikawa W, Nakamura K, Miura D, Shimizu J, Hashimoto K, Kataoka N, Toyota H, Okuyama H, Miyoshi T, Morita H, Fukushima Kusano K, Matsuo T, Takaki M, Kajiya F, Yagi N, Ohe T, Ito H.

Circ J. 2013;77(3):741-8. Epub 2012 Dec 6.

11.

Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.

Nakamura K, Akagi S, Ogawa A, Kusano KF, Matsubara H, Miura D, Fuke S, Nishii N, Nagase S, Kohno K, Morita H, Oto T, Yamanaka R, Otsuka F, Miura A, Yutani C, Ohe T, Ito H.

Int J Cardiol. 2012 Aug 23;159(2):100-6. doi: 10.1016/j.ijcard.2011.02.024. Epub 2011 Mar 4.

PMID:
21376411
12.

Beta-Blockers and Oxidative Stress in Patients with Heart Failure.

Nakamura K, Murakami M, Miura D, Yunoki K, Enko K, Tanaka M, Saito Y, Nishii N, Miyoshi T, Yoshida M, Oe H, Toh N, Nagase S, Kohno K, Morita H, Matsubara H, Kusano KF, Ohe T, Ito H.

Pharmaceuticals (Basel). 2011 Aug 5;4(8):1088-100. doi: 10.3390/ph4081088. Review.

13.

SCN5A mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with Brugada syndrome.

Nishii N, Ogawa M, Morita H, Nakamura K, Banba K, Miura D, Kumagai N, Matsunaga A, Kawamura H, Urakawa S, Miyaji K, Nagai M, Satoh K, Nakagawa K, Tanaka M, Hiramatsu S, Tada T, Murakami M, Nagase S, Kohno K, Kusano KF, Saku K, Ohe T, Ito H.

Circ J. 2010 Nov;74(12):2572-8. Epub 2010 Oct 30.

14.

Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation.

Murakami M, Nakamura K, Kusano KF, Morita H, Nakagawa K, Tanaka M, Tada T, Toh N, Nishii N, Nagase S, Hata Y, Kohno K, Miura D, Ohe T, Ito H.

J Cardiovasc Pharmacol. 2010 Oct;56(4):389-95. doi: 10.1097/FJC.0b013e3181f03c2f.

PMID:
20625312
15.

Cytokine reducing effect of azelnidipine in human peripheral blood mononuclear cells.

Miura R, Nakamura K, Miura D, Miura A, Kajiya M, Hisamatsu K, Nagase S, Morita H, Kusano KF, Matsubara H, Ohe T, Ito H.

Biol Pharm Bull. 2010;33(7):1148-51.

16.

Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutation.

Tanaka M, Nakamura K, Kusano KF, Morita H, Ohta-Ogo K, Miura D, Miura A, Nakagawa K, Tada T, Murakami M, Nishii N, Nagase S, Hata Y, Kohno K, Ouchida M, Shimizu K, Yutani C, Ohe T, Ito H.

Cardiovasc Pathol. 2011 Jan-Feb;20(1):e37-42. doi: 10.1016/j.carpath.2010.02.002. Epub 2010 Mar 12.

PMID:
20219395
17.

Atrial electrophysiological and structural remodeling in high-risk patients with Brugada syndrome: assessment with electrophysiology and echocardiography.

Toh N, Morita H, Nagase S, Taniguchi M, Miura D, Nishii N, Nakamura K, Ohe T, Kusano KF, Ito H.

Heart Rhythm. 2010;7(2):218-24. doi: 10.1016/j.hrthm.2009.10.035. Epub 2009 Oct 30.

PMID:
20129298
18.

Abnormal restitution property of action potential duration and conduction delay in Brugada syndrome: both repolarization and depolarization abnormalities.

Nishii N, Nagase S, Morita H, Kusano KF, Namba T, Miura D, Miyaji K, Hiramatsu S, Tada T, Murakami M, Watanabe A, Banba K, Sakai Y, Nakamura K, Oka T, Ohe T.

Europace. 2010 Apr;12(4):544-52. doi: 10.1093/europace/eup432. Epub 2010 Jan 17.

PMID:
20083482
19.
20.

Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension.

Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H, Ogawa A, Miura A, Miura D, Oto T, Yamanaka R, Otsuka F, Date H, Ohe T, Ito H.

J Cardiovasc Pharmacol. 2010 Jan;55(1):39-48. doi: 10.1097/FJC.0b013e3181c0419c.

PMID:
19786891

Supplemental Content

Loading ...
Support Center